
Zymeworks Inc.
80
Recent developments for Zymeworks include clinical progress, strategic licensing and acquisition deals, updated financial guidance, and earnings reports reflecting operational and financial activities.
- Zymeworks announced licensing of cancer drug candidate ZW209 to Roche in a deal worth up to $813 million [N4].
- The company highlighted positive ovarian cancer responses for ZW191 and potential upside from the Roche deal [N3].
- Zymeworks completed the acquisition of Theravance, adding YUPELRI cash flow and raising its 2026 financial outlook [N5].
- Updated 2026 financial guidance was issued by Zymeworks reflecting adjustments to its outlook [N6].
- Zymeworks reported Q3 results with net income and earnings per share figures disclosed in its 10-Q filing [S2].
- The company secured a $250 million royalty funding deal with Royalty Pharma linked to FDA approval of Ziihera in gastroesophageal adenocarcinoma [N9].
- Zymeworks acquired TBPH, which met Q2 earnings estimates prior to acquisition [N8].
Zymeworks Inc. operates in the biopharmaceutical sector, developing and commercializing therapeutic candidates primarily in oncology. The company engages in licensing agreements with major pharmaceutical firms such as Roche and has expanded its portfolio through acquisitions including Theravance and TBPH. Its clinical pipeline includes candidates like ZW191 and ZW209, with ongoing Phase 3 studies and regulatory milestones. Financially, Zymeworks reported profitability in Q3 2026 and maintains strong liquidity positions. The company actively communicates strategic priorities and financial outlook through regular earnings reports and news releases.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Zymeworks Inc. is a biopharmaceutical company focused on oncology therapeutics with active clinical development and strategic partnerships. The company reported net income of $173.7 million and basic EPS of $2.43 for Q3 2026, with strong liquidity metrics as of September 30, 2026. Recent developments include licensing deals with Roche, acquisition of Theravance and TBPH, positive clinical trial results, and updated financial guidance for 2026.
Zymeworks has demonstrated clinical progress with positive Phase 3 results for Ziihera and ovarian cancer responses for ZW191, supporting its therapeutic pipeline. Strategic licensing deals, such as the $813 million agreement with Roche for ZW209, and acquisitions like Theravance and TBPH, expand its commercial footprint and cash flow. Strong liquidity and profitability metrics as of Q3 2026 provide financial flexibility to advance development and commercialization activities.
Risks include the inherent uncertainties of clinical development and regulatory approvals in the biopharmaceutical industry. Dependence on partnerships and licensing agreements exposes the company to counterparty risks. Integration challenges from recent acquisitions and potential market competition could impact operational execution. Financial performance may be affected by variability in clinical outcomes, reimbursement environments, and capital market conditions.
Zymeworks' moat is supported by its proprietary therapeutic candidates in oncology, strategic partnerships with established pharmaceutical companies like Roche, and its ability to secure significant licensing deals and royalty funding. Its clinical development progress and acquisitions enhance its product pipeline and potential revenue streams. The company's liquidity and financial resources provide operational stability to support ongoing research and commercialization efforts.
• Clinical and Regulatory Risk: The success of Zymeworks depends on the outcomes of clinical trials and regulatory approvals for its therapeutic candidates, which are inherently uncertain and may delay or prevent commercialization.
• Partnership and Licensing Risk: The company relies on collaborations and licensing agreements, such as with Roche, which may be subject to renegotiation, termination, or performance issues affecting revenue and development.
• Acquisition Integration Risk: Recent acquisitions like Theravance and TBPH require effective integration to realize expected benefits; failure to do so could disrupt operations and financial performance.
• Market and Competitive Risk: Zymeworks operates in a competitive biopharmaceutical market with potential for competing therapies that could limit market share and pricing power.
Business trends: Continued clinical development in oncology therapeutics, strategic licensing deals with major pharma, and expansion through acquisitions.
Execution milestones: Completion of licensing agreements, integration of acquisitions, and delivery of updated financial guidance.
Key risks: Clinical and regulatory uncertainties, partnership dependencies, acquisition integration challenges, and competitive market pressures.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Zymeworks Inc. is a biopharmaceutical company engaged in developing and commercializing therapeutic candidates, including cancer drug candidates.
- The company has licensed the cancer drug candidate ZW209 to Roche in a deal worth up to $813 million, indicating collaboration with a major pharmaceutical partner [N4].
- Zymeworks completed the acquisition of Theravance, adding YUPELRI cash flow and raising its 2026 financial outlook [N5].
- The company reported positive clinical responses for ZW191 in ovarian cancer, highlighting ongoing clinical development efforts [N3].
- Zymeworks secured a $250 million royalty funding deal with Royalty Pharma, providing capital linked to FDA approval of Ziihera in gastroesophageal adenocarcinoma (GEA) cancers [N9].
- The company demonstrated positive Phase 3 study results for Ziihera in gastroesophageal adenocarcinoma [N10].
- Zymeworks announced the acquisition of TBPH, which met Q2 earnings estimates prior to acquisition [N8].
- The company reported a net income of $173.7 million and basic earnings per share of $2.43 for the quarter ended September 30, 2026, according to its 10-Q filing [S2].
- As of September 30, 2026, Zymeworks held $100.5 million in cash and cash equivalents and had current assets of $532.4 million against current liabilities of $161.5 million, resulting in a current ratio of 3.3 and a cash ratio of 1.96, indicating strong liquidity [S2].
- Zymeworks issued updated financial guidance for 2026, reflecting adjustments to its outlook [N6].
- The company has ongoing clinical and commercial activities related to oncology therapeutics, including collaborations and licensing agreements.
- Recent news coverage includes multiple earnings reports, clinical updates, and strategic transactions, reflecting active business operations and investor communications.
Generated 2026-11-09
- S1 | 2026-03-02 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-04 | www.nasdaq.com | Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know | https://www.nasdaq.com/articles/will-alvotech-alvo-report-negative-earnings-next-week-what-you-should-know
- N2 | 2026-10-29 | www.nasdaq.com | Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth | https://www.nasdaq.com/articles/zymeworks-inc-zyme-report-q3-results-wall-street-expects-earnings-growth
- N3 | 2026-10-27 | www.nasdaq.com | Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside | https://www.nasdaq.com/articles/zymeworks-highlights-zw191-ovarian-cancer-responses-roche-deal-upside
- N4 | 2026-10-23 | www.nasdaq.com | Zymeworks Licenses Cancer Drug Candidate ZW209 To Roche In Deal Worth Up To $813 Million | https://www.nasdaq.com/articles/zymeworks-licenses-cancer-drug-candidate-zw209-roche-deal-worth-813-million
- N5 | 2026-10-02 | www.nasdaq.com | Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook | https://www.nasdaq.com/articles/zymeworks-completes-theravance-deal-adds-yupelri-cash-flow-and-raises-2026-outlook
- N6 | 2026-09-28 | www.nasdaq.com | Zymeworks Issues Updated 2026 Financial Guidance | https://www.nasdaq.com/articles/zymeworks-issues-updated-2026-financial-guidance
- N7 | 2026-09-01 | www.nasdaq.com | JAZZ Rises on Updated OS Results From Gastric Cancer Study | https://www.nasdaq.com/articles/jazz-rises-updated-os-results-gastric-cancer-study
- N8 | 2026-08-11 | www.nasdaq.com | TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks | https://www.nasdaq.com/articles/tbph-meets-q2-earnings-estimates-be-acquired-zymeworks
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


